Sirolimus-eluting coronary stent - Terumo
Alternative Names: Rapamycin-eluting coronary stent - Terumo; TCD-10023; UltimasterLatest Information Update: 30 Dec 2021
Price :
$50 *
At a glance
- Originator Terumo
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery disease
- No development reported Myocardial infarction
Most Recent Events
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Myocardial-infarction in Japan (Intracoronary, Implant)
- 28 Mar 2019 Terumo completes a clinical trial in Myocardial infarction in Japan (Intracoronary) (UMIN000021549)
- 06 Dec 2016 Launched for Coronary artery disease in South Korea (Intracoronary) before December 2016